fibrot
diseas
major
caus
mortal
morbid
worldwid
lead
seriou
econom
burden
challeng
health
servic
fibrosi
caus
repetit
noxiou
stimuli
lead
cell
stress
injuri
apoptosi
caus
organ
dysfunct
ultim
organ
failur
fibrosi
affect
nearli
everi
organ
liver
lung
fibrosi
show
rise
preval
due
lifestyl
chang
unfavor
environment
condit
current
sever
treatment
option
evalu
liver
lung
fibrosi
howev
limit
therapeut
success
rais
need
new
therapeut
approach
investig
underli
mechan
fibrot
diseas
show
dysregul
organspecif
reninangiotensin
system
ra
play
critic
role
diseas
onset
trigger
excess
proinflammatori
profibrot
signal
angiotensinconvert
enzym
famili
member
ra
act
metallocarboxypeptidas
cleav
angiotensin
ii
angii
ang
angii
act
angii
type
receptor
lead
proinflammatori
profibrot
signal
ang
act
ma
oncogen
receptor
ma
receptor
lead
antiinflammatori
antifibrot
signal
thu
shift
ra
balanc
reduc
amount
angii
time
increas
amount
ang
molecul
therefor
reestablish
physiolog
balanc
ra
also
clearli
shift
toward
resolut
inflamm
fibrosi
level
markedli
increas
patient
liver
fibrosi
well
experiment
model
may
due
counterregulatori
respons
ra
upregul
knockout
studi
reveal
loss
lead
exacerb
liver
injuri
attenu
administr
recombin
adenoassoci
gene
therapi
similar
therapeut
effect
shown
administr
ang
sideeffect
angii
receptor
blocker
arb
therapi
interestingli
unlik
observ
liver
fibrosi
level
markedli
decreas
lung
tissu
patient
suffer
idiopath
pulmonari
fibrosi
ipf
murin
model
two
studi
show
intraperiton
inject
exogen
protein
bleomycininduc
lung
fibrosi
led
reestablish
local
level
reduc
level
lung
injuri
protect
effect
could
shown
bleomycininduc
mous
model
intratrach
administr
lentivir
packag
ang
fusion
gene
cdna
rna
transcript
therapi
rtt
gain
substanti
attent
newli
evolv
therapeut
approach
mrna
exert
function
cytoplasm
lead
high
reliabl
transfect
effici
prolifer
well
quiescent
cell
without
risk
insert
mutagenesi
face
viral
vector
plasmid
dna
pdna
comparison
recombin
protein
therapi
rtt
limit
secret
protein
make
interest
altern
translat
intracellular
membranebound
protein
due
enzymat
mrna
degrad
mechan
cytoplasm
protein
translat
control
natur
selflimit
mani
initi
obstacl
mrna
therapi
rna
instabl
immunogen
solv
offer
today
repertoir
techniqu
design
chemic
modifi
mrna
cmrna
tailormad
pharmacodynam
properti
howev
clinic
applic
rtt
still
preclin
stage
owe
challeng
cellor
organspecif
deliveri
complex
mrna
pharmacolog
previous
state
promis
result
therapi
experiment
liver
lung
fibrosi
report
human
clinic
trial
safeti
toler
system
appli
recombin
shown
howev
local
translat
membraneanchor
may
even
favor
may
achiev
recent
advanc
cmrna
technolog
therefor
object
studi
establish
robust
translat
cmrna
liver
lung
respect
first
perform
vitro
valid
cmrna
translat
protein
activ
integr
second
step
design
eight
differ
cmrna
sequenc
screen
cell
cultur
identifi
optim
cmrna
composit
sustain
protein
translat
activ
liver
lung
cell
final
lead
candid
formul
liveror
lungspecif
deliveri
led
increas
translat
protein
select
organ
first
set
experi
investig
rna
deliveri
vitrotranscrib
chemic
modifi
rna
success
translat
protein
gener
test
system
chose
human
embryon
kidney
cell
frequent
use
transient
transfect
experi
aim
liverand
lungtarget
protein
translat
subsequ
vivo
studi
select
alveolar
epitheli
cell
aec
hepatoma
cell
repres
human
cell
line
hepatocyt
lung
fibroblast
repres
primari
murin
cell
first
cell
screen
endogen
level
mrna
figur
endogen
level
pulmonari
cell
either
detect
case
lung
fibroblast
detect
limit
case
cell
cell
show
moder
level
mrna
rel
three
refer
gene
cellular
uptak
cmrna
transfect
analyz
realtim
pcr
figur
cmrna
uptak
quantifi
set
refer
gene
affect
experiment
condit
data
shown
hr
transfect
cmrna
success
taken
cmrnatreat
sampl
cmrna
could
detect
control
cmrna
untransfect
sampl
next
step
aim
verifi
whether
cmrna
success
translat
protein
first
protein
abund
transfect
analyz
western
blot
purpos
cell
transfect
two
dose
cmrna
respect
three
cell
line
show
clear
dosedepend
express
level
protein
figur
likewis
transfect
primari
liver
lung
cell
cmrna
also
led
clearli
detect
protein
level
second
enzymat
activ
protein
analyz
activ
assay
figur
cmrnatransfect
sampl
show
signific
induct
activ
rel
untransfect
sampl
find
demonstr
cmrna
transfect
lead
translat
enzymat
activ
protein
liver
lung
cell
posttransl
modif
glycosyl
integr
plasma
membran
typic
type
integr
membran
protein
core
domain
locat
extracellular
surfac
extracellular
domain
flank
signal
peptid
follow
catalyt
domain
sever
glycosyl
site
crucial
vivo
studi
guarante
local
express
membranebound
version
protein
therefor
specif
investig
posttransl
modif
eg
glycosyl
intramolecular
disulfid
bond
regard
biolog
properti
nlink
glycosyl
pivot
proper
fold
assembl
traffick
membran
protein
therefor
investig
whether
cmrnaderiv
protein
glycosyl
correctli
integr
plasma
membran
cell
transfect
cmrna
produc
protein
size
kda
correspond
matur
fulli
glycosyl
form
protein
glycosyl
process
success
inhibit
treat
cell
tunicamycin
inhibitor
nlink
glycosyl
retrospect
deglycosyl
matur
protein
enzymat
deglycosyl
result
protein
size
inhibit
glycosyl
confirm
full
protein
glycosyl
figur
addit
format
disulfid
bond
shown
figur
verifi
correct
protein
integr
express
cell
surfac
cmrnatransfect
cell
stain
antibodi
recogn
core
domain
locat
cell
surfac
cell
analyz
flow
cytometri
figur
three
cell
line
cmrnatransfect
sampl
show
clear
increas
translat
rel
untransfect
sampl
local
cmrnaderiv
protein
cell
transfect
cmrna
protein
visual
fluoresc
stain
cell
figur
respect
cell
line
sampl
transfect
cmrna
stain
posit
protein
transfect
control
cmrna
show
weak
background
signal
cell
light
potenti
futur
therapeut
applic
lung
liver
fibrosi
endogen
level
protein
suffici
prevent
diseas
onset
progress
henc
strong
translat
pivot
immunocytochem
imag
reveal
protein
local
throughout
cytoplasm
plasma
membran
accumul
found
throughout
cytoplasm
show
dot
pattern
indic
protein
enrich
vesicular
structur
probabl
involv
protein
matur
traffick
plasma
membran
presenc
protein
plasma
membran
indic
coloc
wheat
germ
agglutinin
plasma
membran
marker
white
stain
pattern
overlay
imag
taken
togeth
could
prove
cmrnaderiv
protein
undergo
biolog
posttransl
modif
lead
correct
integr
plasma
membran
codonoptim
cmrna
human
aglobin
utr
lead
enhanc
cmrna
stabil
protein
translat
success
verifi
sequenc
cmrna
lead
translat
activ
membranebound
form
wwwmoleculartherapyorg
protein
want
optim
sequenc
strong
protein
translat
therefor
design
eight
differ
cmrna
sequenc
share
open
read
frame
orf
encod
cap
poli
tail
nucleotid
found
optim
length
addit
natur
mrna
sequenc
introduc
three
differ
modif
utr
known
high
level
protein
translat
name
minim
utr
human
alpha
globin
hag
utr
cytochrom
alpha
polypeptid
cyba
utr
four
sequenc
design
one
natur
version
one
codonoptim
version
orf
first
interest
effect
cmrna
modif
intracellular
cmrna
stabil
overal
cmrna
follow
degrad
pattern
exponenti
onephas
decay
figur
rna
sequenc
detect
hr
transfect
overal
codon
optim
slow
rate
cmrna
degrad
lead
higher
level
cmrna
later
time
point
except
codonoptim
natur
sequenc
highest
number
noncodonoptim
nucleotid
sequenc
due
long
natur
utr
region
base
data
halflif
sequenc
calcul
decay
phase
tabl
cell
codonoptim
sequenc
show
extend
halflif
compar
nativ
sequenc
cell
codon
optim
led
prolong
halflif
hag
minim
cmrna
sequenc
look
translat
effici
codon
optim
led
stronger
protein
translat
cell
line
hr
cell
figur
left
right
panel
respect
strongest
protein
translat
observ
codonoptim
hag
cmrna
follow
codonoptim
minim
cmrna
despit
extend
halflif
codonoptim
cyba
cmrna
protein
abund
could
reach
level
codonoptim
minim
hag
cmrna
data
obtain
western
blot
confirm
activ
assay
cell
figur
left
right
panel
respect
cell
line
enzymat
activ
significantli
increas
sampl
transfect
codonoptim
hag
cmrna
codonoptim
minim
cmrna
rel
untransfect
sampl
base
result
codonoptim
minim
codonoptim
hag
cmrna
identifi
best
perform
sequenc
regard
cmrna
stabil
protein
translat
kinet
codonoptim
hag
cmrna
sequenc
show
slightli
longer
halflif
minim
sequenc
use
subsequ
vivo
studi
dysregul
local
ra
contribut
significantli
inflamm
fibrosi
process
best
counterbalanc
specif
translat
affect
organ
purpos
livertarget
cmrna
deliveri
chose
lipoplex
refer
liver
lipidoid
formul
llf
follow
describ
nska
et
al
liver
specif
llf
first
confirm
formul
firefli
luciferas
cmrna
mgkg
dose
formul
administ
intraven
mice
luciferas
protein
activ
measur
hr
administr
anim
show
strong
select
cmrna
uptak
liver
without
signal
organ
figur
luciferas
protein
express
liver
clearli
mirror
blood
flow
organ
therebi
reflect
lipoplex
distribut
intraven
inject
figur
strong
protein
enrich
observ
close
portal
region
affer
vessel
enter
liver
gradual
decreas
toward
effer
central
vein
success
verifi
target
select
enrich
llfcomplex
cmrna
protein
translat
liver
formul
two
dose
cmrna
mgkg
singl
dose
mgkg
control
cmrna
llf
intraven
inject
mice
hr
treatment
situ
hybrid
liver
cmrnatreat
anim
show
cmrna
uptak
hepatocyt
detect
cmrna
liver
sinusoid
throughout
liver
sampl
less
homogen
pattern
figur
result
confirm
realtim
pcr
show
signific
cmrna
liver
homogen
anim
figur
quantif
deposit
cmrna
show
clear
dosedepend
uptak
ng
cmrnamg
total
rna
dose
cmrnamg
total
rna
dose
cmrna
detect
control
group
cmrna
success
translat
shown
western
blot
analysi
figur
clear
increas
protein
abund
treatment
group
glycosyl
shown
enzymat
deglycosyl
liver
homogen
induc
shift
protein
size
indic
activ
glycosyl
process
vivo
activ
assay
figur
significantli
higher
protein
activ
detect
liver
sampl
control
group
show
endogen
baselin
activ
purpos
pulmonari
cmrna
deliveri
develop
novel
proprietari
lipid
formul
especi
design
lungtarget
cmrna
deliveri
intraven
inject
refer
pulmonari
lipid
formul
plf
follow
first
lung
target
formul
evalu
intraven
applic
luciferas
cmrna
plf
mice
dose
mgkg
hr
inject
strong
luciferas
signal
detect
select
lung
wherea
organ
show
signal
figur
identifi
plf
select
deliveri
agent
lung
applic
formul
mixtur
cmrna
control
cmrna
luciferas
cmrna
plf
dose
formul
administ
intraven
mice
shamtreat
anim
receiv
singl
inject
pb
hr
lungspecif
deliveri
confirm
luciferas
activ
show
high
level
lung
compar
organ
anim
receiv
plf
formul
figur
situ
hybrid
cmrnatreat
anim
show
homogen
distribut
positivestain
cell
alveolar
wall
interpret
type
ii
type
aec
figur
left
panel
furthermor
singl
macrophag
cmrna
found
immunohistochem
stain
protein
anim
reveal
multifoc
membran
posit
stain
cell
locat
predominantli
alveolar
angl
like
type
ii
aec
macrophag
figur
middl
panel
addit
cmrnatreat
anim
wwwmoleculartherapyorg
show
posit
cell
alveolar
wall
strong
membran
moder
cytoplasm
stain
morpholog
cell
indic
type
aec
protein
abund
increas
cmrnatreat
group
control
cmrna
sham
sampl
show
endogen
protein
level
detect
western
blot
figur
overal
applic
cmrna
result
mild
moder
focal
dissemin
free
alveolar
erythrocyt
figur
right
panel
taken
togeth
shown
intraven
administr
lipoplex
codonoptim
hag
cmrna
lipidoid
nanoparticl
llf
plf
abl
strongli
induc
protein
translat
select
liver
lung
reestablish
wellbalanc
ra
repeatedli
shown
promis
therapeut
effect
treatment
liver
lung
fibrosi
effect
may
enhanc
local
translat
affect
organ
feasibl
latest
cmrna
technolog
studi
design
optim
sequenc
chemic
modifi
mrna
lead
promin
protein
translat
activ
vitro
vivo
tailormad
lipidoidbas
formul
optim
cmrna
sequenc
led
protein
translat
directli
select
liver
lipidbas
formul
pulmonari
deliveri
result
select
translat
lung
use
cmrna
ra
signal
cascad
produc
multipl
biolog
activ
intermedi
initi
drug
develop
mainli
focus
ace
inhibitor
context
blood
pressur
regul
howev
increas
knowledg
physiolog
patholog
properti
biolog
intermedi
proteolyt
cascad
receptor
blocker
receptor
agonist
recombin
activ
ang
analog
gain
momentum
except
therapeut
purpos
drug
either
reduc
proinflammatori
profibrot
signal
receptor
counterbal
receptor
signal
increas
ma
receptor
signal
effect
regul
howev
uniqu
ra
achiev
cleav
angii
ang
reduc
stimul
receptor
signal
time
increas
antiinflammatori
antifibrot
signal
ma
receptor
therapeut
effect
modul
ra
increas
signal
describ
repeatedli
shown
liver
lung
fibrosi
howev
previou
studi
struggl
hurdl
organspecif
deliveri
control
protein
express
immunogen
among
other
posttransl
modif
glycosyl
indispens
full
function
protein
subject
modif
especi
membraneintegr
protein
guarante
recombin
protein
therapi
obstacl
requir
could
potenti
solv
rtt
henc
aim
investig
potenti
rtt
thu
design
vitrotranscrib
chemic
modifi
mrna
sequenc
sequenc
success
test
vitro
cellular
cmrna
uptak
translat
enzymat
activ
protein
gener
test
system
cell
well
human
murin
pulmonari
hepatocellular
cell
figur
administr
recombin
human
experiment
liver
lung
fibrosi
show
first
promis
result
howev
longterm
effect
collagen
deposit
lung
consid
question
increas
need
local
deliveri
greater
efficaci
two
requir
feasibl
latest
advanc
rtt
addit
limit
understand
physiolog
relev
solubl
limit
termin
halflif
hr
recombin
protein
human
urg
us
verifi
cmrnaderiv
protein
process
stabli
express
transmembran
protein
verifi
full
protein
glycosyl
vitro
vivo
figur
crucial
step
protein
traffick
integr
plasma
membran
confirm
correct
protein
integr
plasma
membran
figur
fluoresc
stain
cmrnatransfect
cell
could
observ
enrich
vesicular
structur
may
part
posttransl
matur
machineri
figur
howev
detail
analysi
posttransl
modif
relev
would
requir
complet
assess
consensu
endogen
cmrnaderiv
protein
process
potenti
futur
applic
rtt
human
care
consider
biochem
properti
relat
biolog
implic
pharmacokinet
pharmacodynam
requir
therefor
optim
cmrna
sequenc
regard
cmrna
stabil
protein
abund
enzymat
activ
translat
kinet
base
group
work
decid
set
modif
consid
promis
purpos
cell
type
cell
state
strong
impact
cell
react
variat
artifici
introduc
mrna
sequenc
biolog
implic
modif
need
care
evalu
utr
key
element
mrna
sequenc
translat
initi
elong
termin
well
intracellular
local
mrna
stabil
signific
impact
final
protein
express
kinet
therefor
design
sequenc
three
utr
modif
minim
utr
known
high
level
protein
translat
extend
time
period
codon
optim
anoth
techniqu
frequent
use
strong
protein
translat
techniqu
translat
rate
markedli
increas
replac
rare
codon
abund
codon
without
modifi
amino
acid
sequenc
encod
protein
addit
codon
optim
reduc
secondari
structur
cmrna
may
otherwis
induc
cellular
immun
reaction
therefor
four
sequenc
design
one
natur
version
one
codonoptim
version
orf
screen
cell
figur
observ
codon
optim
also
led
increas
halflif
cmrna
sequenc
cell
cell
protein
translat
howev
markedli
increas
legend
next
page
hr
cell
line
codonoptim
sequenc
could
increas
protein
translat
enzymat
activ
also
replac
natur
utr
utr
strongli
translat
protein
differ
utr
affect
physic
halflif
cmrna
tabl
conclud
replac
utr
primarili
increas
translat
effici
line
previou
find
purpos
liverand
lungtarget
applic
cmrna
could
identifi
codonoptim
hag
cmrna
best
perform
sequenc
furthermor
observ
codon
optim
hag
cmrna
sequenc
led
reduc
immunogen
figur
probabl
lead
prolong
halflif
strong
protein
translat
day
cell
line
celland
tissuespecif
deliveri
cmrna
current
consid
major
obstacl
overcom
rtt
could
show
intraven
deliveri
report
cmrna
llf
describ
nska
et
al
led
strong
liverspecif
protein
translat
figur
immunohistochem
stain
indic
intraven
applic
potent
deliveri
mechan
reach
high
number
hepatocyt
previous
shown
deliveri
small
interf
rna
sirna
well
mrna
current
understand
underli
mechan
lipoplex
enter
liver
lobuli
via
fenestr
capillari
lack
diaphragm
unlik
type
capillari
make
highli
permeabl
small
molecul
lipoplex
easili
taken
interstitium
transport
ligandbas
target
diffus
affer
effer
vessel
visibl
histochem
stain
luciferas
protein
show
gradual
decreas
protein
abund
affer
effer
vessel
figur
effect
observ
throughout
whole
organ
confirm
advantag
rtt
recombin
protein
therapi
pdna
deliverynam
reach
larg
pool
cell
even
beyond
physic
barrier
endothelium
mitot
nonmitot
cell
postul
previous
matsui
et
al
aim
shift
local
balanc
ra
toward
resolut
fibrosi
consid
reach
hepatocyt
abund
cell
type
liver
major
achiev
strong
translat
target
protein
second
step
appli
deliveri
method
cmrna
saw
markedli
increas
protein
translat
activ
hr
treatment
figur
vitro
find
figur
show
protein
detect
day
express
pattern
establish
futur
vivo
model
rtt
express
lie
level
reach
recombin
therapi
human
level
reach
adenoassoci
viral
therapi
experiment
model
emphas
advantag
rtt
flexibl
dose
regimen
potenti
futur
clinic
applic
choos
optim
administr
rout
lungtarget
cmrna
deliveri
requir
care
consider
patholog
characterist
target
diseas
ipf
character
aec
apoptosi
respons
repetit
microinjuri
effect
particularli
evid
adjac
fibroblast
foci
previou
vitro
studi
shown
aec
produc
angii
respons
injuri
mrna
reduc
time
make
aec
even
prone
injuri
angiiinduc
apoptosi
therefor
consid
deliv
cmrna
especi
area
epitheli
cell
death
essenti
therapeut
success
due
scar
lung
parenchyma
area
poorli
ventil
hinder
uptak
drug
via
airway
look
vascular
fibrot
lung
shown
fibroblast
foci
poorli
vascular
adjac
nonfibrot
area
aec
apoptosi
take
place
highli
vascular
therefor
hypothes
may
effect
reach
area
via
pulmonari
vasculatur
via
airway
thu
use
lipidbas
cmrna
formul
plf
optim
pulmonari
deliveri
intraven
applic
mice
formul
show
strong
select
protein
translat
lung
figur
administr
plf
contain
cmrna
led
equal
strong
protein
translat
lung
figur
immunostain
show
shamtreat
anim
express
type
ii
aec
alreadi
observ
wiener
et
al
cmrnatreat
lung
presum
also
express
type
aec
find
especi
valuabl
therapeut
applic
ipf
unlik
rodent
lung
human
lung
also
express
type
aec
render
enorm
pool
local
activ
protein
break
viciou
circl
angiistimul
downregul
apoptosi
establish
translat
type
aec
could
achiev
recombin
protein
therapi
lentiviralmedi
overexpress
summari
advanc
latest
rna
technolog
sustain
local
translat
liver
lung
achiev
highlight
strength
rtt
recombin
protein
therapi
protein
halflif
immunogen
organor
celltarget
deliveri
still
challeng
compar
nonvir
gene
transfer
pdna
rtt
show
strong
translat
effici
without
risk
insert
mutagenesi
problem
also
found
retrovir
lentivir
adenoassoci
gene
transfer
addit
time
frame
viralmedi
gene
express
difficult
control
last
year
case
adenoassoci
virus
furthermor
contrast
gene
therapi
cell
divis
need
success
protein
express
rtt
studi
design
cmrna
sequenc
lead
strong
stabl
protein
translat
vitro
vivo
combin
select
lipidoid
lipid
nanoparticl
serv
carrier
system
abl
translat
protein
select
liver
lung
may
allow
reestablish
local
ra
balanc
due
selflimit
translat
without
risk
genom
integr
protein
translat
finetun
patient
need
control
treatment
durat
halt
resolut
fibrosi
therefor
consid
rtt
promis
approach
treatment
liver
lung
fibrosi
test
fibrot
diseas
model
chemic
modifi
mrna
synthes
previous
describ
brief
respect
pdna
templat
subject
vitro
transcript
use
rna
polymeras
thermo
fisher
scientif
predefin
mix
natur
chemic
modifi
ribonucleotid
enhanc
rna
stabil
cap
structur
enzymat
ad
end
transcript
end
subject
polyadenyl
nucleotid
cmrna
product
purifi
ammoniumacet
precipit
resuspend
water
desir
concentr
puriti
qualiti
check
spectrophotomet
thermo
fisher
scientif
standard
sensit
rna
analysi
kit
fragment
analyz
advanc
analyt
technolog
follow
cmrna
sequenc
design
human
livertarget
vivo
experi
cmrna
formul
llf
previous
describ
lungtarget
lipoplex
plf
prepar
mix
cmrna
inhous
polyethylen
glycol
peg
copolym
aqueou
solut
appli
mix
preassembl
lipid
micel
incub
min
rt
selfassembl
cmrna
plf
mix
transfer
dulbecco
pb
thermo
fisher
scientif
supplement
sucros
lipoplex
appli
final
volum
ml
per
anim
cmrna
dose
mgkg
panbiotech
cell
attach
medium
chang
cultur
medium
supplement
fc
fibroblast
extract
perform
excis
lung
wildtyp
mice
intraperiton
overdos
ketaminexylazin
cervic
disloc
steril
condit
lung
flush
pb
cannul
right
ventricl
flush
lung
excis
dice
piec
digest
media
collagenas
solut
contain
lglutamin
mm
hepe
gibcolif
technolog
supplement
uml
collagenas
type
biochrom
digest
tissu
filter
wash
pb
seed
cultur
medium
contain
lglutamin
mm
hepe
heatinactiv
fc
gibcolif
technolog
penicillinstreptomycin
gibcolif
technolog
experi
perform
passag
cell
cultur
humidifi
co
incub
c
exchang
cultur
medium
everi
day
cell
cultur
human
cell
line
cell
purchas
dsmz
cultur
minimum
essenti
media
mem
glutamax
gibcolif
technolog
cell
purchas
dsmz
cultur
rpmi
plu
glutamax
gibcolif
technolog
within
year
vitro
experi
crosscontamin
check
short
tandemrepeat
profil
medium
three
cell
line
supplement
heatinactiv
fc
gibcolif
technolog
penicillin
streptomycin
gibcolif
technolog
cell
cultur
humidifi
co
incub
c
cell
cultur
medium
cell
renew
twice
week
cell
passag
confluenc
total
rna
isol
cell
cultur
tissu
sampl
use
nucleospin
rna
plu
kit
macherynagel
total
rna
transcrib
cdna
use
transcriptor
firststrand
cdna
synthesi
kit
roch
diagnost
realtim
qpcr
perform
ssoadvanc
univers
sybr
green
supermix
biorad
roch
light
cycler
roch
diagnost
follow
primer
use
cmrna
vitro
experi
ggccaatcactacg
nativ
cmrna
construct
screen
gccatctaccccattt
codonoptim
cmrna
construct
screen
aata
human
human
bactin
primepcr
sybr
green
assay
biorad
human
tatabind
protein
primepcr
sybr
green
assay
human
human
mitochondri
ribosom
protein
ggaatgtt
human
succin
dehydrogenas
subunit
sdha
mous
tgtagaacgtaccttcgc
mous
hypoxanthineguanin
phosphoribosyltransferas
hprt
mous
cgagtacagcacc
mous
sdha
ttgagat
mous
glucuronidas
beta
gusb
primepcr
sybr
green
assay
refer
gene
use
figur
bactin
tatabox
bind
protein
human
sampl
gusb
sdha
hepatocyt
hprt
lung
fibroblast
absolut
cmrna
valu
calcul
interpol
use
graphpad
prism
softwar
halfliv
confid
interv
calcul
appli
onephas
exponenti
decay
function
automat
outlier
elimin
graphpad
prism
softwar
vitro
experi
cell
lyse
triton
lysi
buffer
nacl
mm
zncl
mm
trishcl
ph
ex
vivo
sampl
lyse
ripa
buffer
mm
tri
ph
mmoll
nacl
triton
sodium
deoxychol
sodium
dodecyl
sulfat
total
protein
content
determin
bicinchonin
acid
bca
assay
follow
manufactur
instruct
thermo
fisher
scientif
applic
part
lysat
use
deglycosyl
neb
protein
deglycosyl
mix
ii
follow
manufactur
instruct
denatur
condit
new
england
biolab
cell
lysat
separ
polyacrylamid
gel
thermo
fisher
scientif
transfer
polyvinyliden
fluorid
pvdf
membran
biorad
membran
block
gelatin
buffer
mm
tri
ph
mm
nacl
triton
mm
edta
gelatin
probe
antibodi
mgml
r
systemsbiotechn
dehydrogenas
gapdh
cell
signal
technologynew
england
biolab
protein
detect
horseradish
peroxidas
hrp
conjug
antigoat
antirabbit
santa
cruz
biotechnolog
antibodi
ad
signal
detect
luminata
western
hrp
substrat
appli
accord
manufactur
protocol
merck
chemic
quantifi
activ
cell
cultur
sampl
lyse
western
blot
activ
assay
adapt
pedersen
et
al
mg
total
protein
extract
incub
without
bachem
min
rt
reaction
buffer
mm
synthet
substrat
mcayvadapk
dnp
oh
r
system
ad
total
volum
ml
incub
least
min
c
ex
vivo
sampl
prepar
describ
joyner
et
al
brief
frozen
liver
lung
sampl
homogen
reaction
buffer
complet
roch
diagnost
contain
nm
hepe
buffer
nm
nacl
mm
zncl
ph
follow
centrifug
g
min
supernat
collect
spun
min
g
result
pellet
wwwmoleculartherapyorg
resuspend
reaction
buffer
overnight
incub
triton
c
gentl
shake
sampl
centrifug
min
g
supernat
collect
total
protein
content
measur
bca
assay
assay
mg
protein
incub
min
rt
reaction
buffer
contain
mm
captopril
santa
cruz
biotechnolog
ace
inhibitor
mm
exclus
chemistri
anoth
inhibitor
ad
follow
anoth
incub
min
rt
final
mm
substrat
mcaapk
dnp
caslo
ad
sampl
incub
hr
c
fluoresc
sampl
measur
tecan
infinit
pro
plate
reader
excit
nm
emiss
nm
correct
protein
integr
plasma
membran
assess
flow
cytometri
cell
wash
pb
detach
trypl
gibcolif
technolog
resuspend
flow
cytometri
buffer
pb
supplement
fc
cell
incub
primari
antibodi
mgml
r
system
flow
cytometri
buffer
hr
c
wash
flow
cytometri
buffer
antigoat
antibodi
thermo
fisher
scientif
ad
hr
c
cell
wash
flow
cytometri
buffer
stain
propidium
iodid
discrimin
live
dead
cell
mgml
sigmaaldrich
analysi
perform
attun
acoust
focus
cytomet
life
technolog
attun
cytometr
softwar
version
life
technolog
flowjo
version
detect
firefli
luciferas
activ
mg
frozen
lung
tissu
lyse
luciferas
lysi
buffer
mice
anesthet
follow
mg
intraperiton
mg
intranas
applic
dluciferin
substrat
synchem
dissolv
pb
mgml
ph
bioluminesc
measur
min
later
use
ivi
lumina
xr
imag
system
calip
life
scienc
exposur
time
min
organ
excis
place
petri
dish
reimag
ivi
system
anim
studi
perform
balbc
mice
anim
purchas
charl
river
laboratori
week
age
weigh
g
start
experi
studi
approv
govern
upper
bavaria
norddeutsch
landesamt
verbraucherschutz
und
lebensmittelsicherheit
lave
germani
anim
experi
carri
accord
guidelin
german
law
protect
anim
life
review
local
ethic
committe
cell
cultur
coverslip
sixwel
plate
wash
pb
mgml
tetramethylrhodamineconjug
wheat
germ
agglutinin
thermo
fisher
scientif
hank
balanc
salt
solut
gibcolif
technolog
ad
sampl
incub
min
incub
sampl
wash
pb
fix
paraformaldehyd
min
rt
cell
wash
incub
min
triton
rt
anoth
wash
step
cell
block
pb
supplement
fc
triton
min
rt
slide
incub
hr
primari
antibodi
mgml
r
system
rt
follow
anoth
wash
step
secondari
antigoat
antibodi
thermo
fisher
scientif
dapi
mgml
sigmaaldrich
ad
incub
hr
rt
final
wash
slide
mount
fluorsav
merck
chemic
view
leica
microscop
leica
microsystem
liver
lung
tissu
excis
fix
hr
buffer
formaldehyd
solut
embed
paraffin
histolog
examin
tissu
section
slice
deparaffin
rehydr
grade
ethanol
seri
antigen
retriev
tissu
section
incub
mm
citrat
buffer
ph
min
use
waterbath
c
wash
pb
quench
min
h
anoth
wash
step
section
luciferas
block
hr
rt
hors
serum
pb
vector
laboratori
section
incub
primari
antiluciferas
antibodi
promega
pb
supplement
triton
c
overnight
tissu
section
wash
pb
incub
immpress
reagent
vector
laboratori
min
rt
wash
pb
diaminobenzidin
substrat
mgml
pb
ad
min
rt
stain
tissu
section
addit
subject
avidinbiotin
block
vector
laboratori
min
rt
follow
brief
wash
tissu
block
vectastain
serumblock
reagent
vector
laboratori
min
rt
follow
overnight
incub
c
primari
antibodi
mgml
r
system
normal
goat
serum
life
technolog
pb
supplement
triton
wash
pb
section
incub
vectastain
biotinyl
antigoat
immunoglobulin
g
igg
dilut
accord
manufactur
protocol
vector
laboratori
wash
incub
vectastain
abc
reagent
vector
laboratori
min
rt
diaminobenzidin
substrat
ad
mgml
pb
min
rt
reaction
stop
wash
tissu
section
distil
water
counterstain
hematoxylin
roth
section
evalu
leica
led
microscop
leica
microsystem
situ
hybrid
liver
tissu
perform
advanc
cell
diagnost
acd
lung
tissu
analyz
item
use
brown
rnascop
hd
reagent
kit
catalog
acd
follow
manufactur
instruct
detect
cmrna
target
probe
design
acd
base
cmrna
sequenc
provid
probe
detect
murin
deriv
genbank
genbank
rnascop
dapb
bacteri
dapb
acd
use
neg
control
rnascop
ppib
cyclophilin
b
acd
posit
control
sampl
counterstain
hematoxylin
view
brightfield
microscop
experi
perform
least
three
technic
replic
per
sampl
addit
quantit
analysi
fluorescenceactiv
cell
sort
fac
sampl
screen
best
perform
cmrna
construct
perform
minimum
three
biolog
replic
result
shown
mean
sd
unless
otherwis
state
statist
analysi
perform
use
graphpad
prism
softwar
version
pairwis
comparison
vitro
experi
conduct
twotail
student
test
group
comparison
vivo
experi
done
oneway
anova
follow
dunnett
multiplecomparison
test
p
valu
consid
statist
signific
laboratori
work
done
ethri
gmbh
institut
lung
biolog
diseas
helmholtz
zentrum
munich
institut
molecular
immunolog
experiment
oncolog
studi
support
biochanc
project
fund
feder
ministri
educ
research
bmbf
deutsch
forschungsgemeinschaft
dfg
via
nanosystem
initi
munich
nim
excel
cluster
thank
member
ethri
gmbh
technic
support
discuss
acknowledg
jana
lambrecht
contribut
regard
pkr
activ
katrin
lindner
support
histolog
process
vivo
sampl
philipp
beck
help
setup
activ
assay
